Fate of Transcept's sole clinical project hangs in balance after missed endpoint
This article was originally published in Scrip
Executive Summary
Transcept Pharmaceuticals will outline the future - or demise - of TO-2061 (ondansetron oral tablets 0.5mg and 0.75mg) in early 2013 in response to the add-on therapy's missed primary efficacy endpoint in a Phase II clinical trial, which looked for an improvement in obsessive compulsive disorder (OCD) symptoms versus placebo.